The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to provide a significant substantial loss in body size and improve metabolic health, particul… Read More